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Abstract 
Background: Allergic rhinitis affects around one quarter of the Western European population. Prophylactic allergen 
immunotherapy may be useful to reduce the risk of acute symptomatic attacks (hayfever). A five‑grass pollen extract 
sublingual immunotherapy (5GPE‑SLIT) has been developed for the treatment of allergic rhinitis to grass pollen. The 
objective of this study was to describe real‑world treatment patterns with 5GPE‑SLIT in France with respect to the 
prescribing information.
Methods: This prospective cohort study was conducted by 90 community and hospital allergists. Adults and chil‑
dren (> 5 years old) starting a first treatment with 5GPE‑SLIT prior to the 2015 pollen season were eligible. Data was 
collected at the inclusion visit and at the end of the pollen season. The primary outcome variable was compatibility of 
5GPE‑SLIT prescription with the prescribing information. This was determined with respect to four variables: (1) inter‑
val between 5GPE‑SLIT initiation and onset of the pollen season ≥ 3 months, (2) age of patient ≥ 5 years, (3) intermit‑
tent symptoms or mild symptom severity (4) confirmatory diagnostic test. At study end, symptoms reported during 
the pollen season and any modifications to treatment or adverse events were documented.
Results: 280 adults and 203 children were enrolled. The prescribing information was respected for 82.5% of adults 
and 86.7% of children. A skin test was performed for all patients. 5GPE‑SLIT was started 3–5 months before the pol‑
len season for 85.3%. Treatment was discontinued before the start of the pollen season in 11.0% of patients overall, 
generally because of an adverse event (78.8% of discontinuations). The mean duration of treatment was 5.2 months in 
adults and 5.6 months in children. At the end of follow‑up, symptoms during the pollen season were intermittent for 
75.0% of adults and 85.7% of children, and severity was mild for 61.8 and 66.0% respectively. During 5GPE‑SLIT, the fol‑
lowing symptoms reported during the previous year were not reported again in > 50% of patients: nasal congestion, 
rhinorrhoea, repeated sneezing, conjunctivitis and nasal pruritus.
Conclusions: 5GPE‑SLIT use was generally consistent with prescribing recommendations and was associated with an 
improvement of AR severity, with resolution of the principal AR symptoms in around half the patients treated.
Trial registration EUPAS9358. Registered 13 May 2015. Not prospectively registered. http://www.encep p.eu/encep p/
viewR esour ce.htm?id=16229 
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Background
Allergic rhinitis is a frequent and debilitating condition 
characterised by inflammation of the nasal epithelium in 
response to an airborne environmental allergen, leading 
to symptoms of rhinorrhoea, repetitive sneezing, blocked 
nose and nasal irritation [1, 2]. The prevalence of clini-
cally-confirmed allergic rhinitis in the general popula-
tion in Western Europe has been estimated as 23% (24.5% 
in France) [3], and other general population studies in 
France using screening questionnaires in telephone inter-
views have yielded similar prevalence rates [4]. Allergic 
rhinitis is associated with deteriorated quality of life [5–
7] and comorbidity with a number of other conditions, 
notably asthma and sleep disturbances [7, 8]. The allergic 
rhinitis and its impact on asthma (ARIA) working group 
has proposed a classification of allergic rhinitis into per-
sistent versus intermittent and mild versus moderate-
severe, which is now generally accepted [2]. In Western 
Europe, grass pollens are a major source of allergens 
responsible for allergic rhinitis, [9] with around half of all 
subjects with allergic rhinitis identified in a general pop-
ulation survey testing positive for grass-pollen-specific 
IgE [3]. A survey in South-East France found that pollen-
specific IgEs were detectable in 11% of a random sample 
of the general population [10].
Historically, conventional treatment of allergic rhinitis 
has been principally symptomatic, through use of oral 
or topical antihistamines as needed to relieve symptoms 
[11]. In patients with moderate or severe persistent aller-
gic rhinitis, the most recent ARIA guidelines recom-
mend long-term prophylactic therapy with intranasal 
corticosteroids, a second-generation antihistamine or a 
leukotriene antagonist [2]. In case of failure of pharma-
cotherapy, allergen immunotherapy should be considered 
[2]. Allergen immunotherapy involves administering high 
doses (either directly of after up-titration from on initial 
low dose, of a specific allergen source in order to induce 
tolerance to it by rebalancing the immune system and 
thereby to reduce the risk of a symptomatic allergic reac-
tion when the patient is exposed to the causative agent 
[11, 12]. Allergen immunotherapy can be administered 
by either the subcutaneous (SCIT) or sublingual (SLIT) 
route. The sublingual route has been better validated in 
clinical trials and appears to be safer [13]. A number of 
SLIT preparations have been introduced into clinical 
practice over the last decade.
In the case of allergic rhinitis triggered by grass pollen, 
a SLIT preparation has been developed containing pollen 
allergens from five common grasses, namely cock’s-foot 
(Dactylis glomerata L.), sweet vernal grass (Anthox-
anthum odoratum L.), perennial ryegrass (Lolium per-
enne L.), common meadow-grass (Poa pratensis L.) and 
meadow cat’s-tail (Phleum pratense L.). This five-grass 
pollen extract SLIT (5GPE-SLIT) is administered in 
the form of 100 and 300  mg sublingual tablets around 
4 months before the beginning of the pollen season until 
the end of the season.
The efficacy and safety of 5GPE-SLIT has been demon-
strated in three large randomised clinical trials [14–16] 
to be effective in preventing symptoms of allergic rhini-
tis due to grass pollen and to be well tolerated. In conse-
quence, this treatment is now approved in Europe and in 
the USA as a prescription medication for the treatment 
of grass pollen allergic rhinitis with or without conjunc-
tivitis in adults, adolescents and children (above the age 
of 5) with clinically relevant symptoms, confirmed by a 
positive skin test or a positive titre of specific grass pollen 
IgE.
However, there is little information on how 5GPE-
SLIT is used in everyday clinical practice or on its effec-
tiveness and tolerability outside the context of a clinical 
trial. The primary objective of the present study was to 
describe indications for 5GPE-SLIT, treatment period 
and concomitant allergy medications under real-world 
conditions during the 2015 pollen season. Secondary 
objectives were to describe the characteristics of the pre-
scribing physicians and the treated patients and to docu-
ment treatment discontinuation and the occurrence of 
any adverse events.
Methods
This was a prospective cohort study conducted in France 
of patients starting treatment with 5GPE-SLIT for the 
2015 pollen season and followed throughout the pol-
len season. The conduct of the study was supervised by 
a steering committee composed of two allergists and a 
biostatistician. The study was mandated by the French 
Health Technology Assessment agency (HAS; Haute 
Autorité de la Santé) as a post-marketing commitment at 
the time of approval of the medication in France, and the 
study protocol was approved by the HAS.
Participating physicians
The study was conducted by community and hospital 
allergists identified from an exhaustive national list. All 
allergists on this list were contacted and invited to par-
ticipate in the study and all allergists who accepted to 
participate were enlisted.
Patients
Each participating physician was expected to enrol all 
patients fulfilling the eligibility criteria attending a con-
sultation during a 3  month period between December 
2014 and February 2015 (prior to the 2015 pollen season), 
up to a maximum of ten patients per physician. Adults 
and children (aged 5–18 years) who were starting a first 
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treatment with 5GPE-SLIT and who agreed to participate 
in the study were eligible. Patients previously treated by 
5GPE-SLIT, participants in clinical trials, patients unable 
to complete the study questionnaires and patients who 
were not expected to be followed throughout the pollen 
season (for example, patients planning to move house) 
were excluded.
A reference set of patients representative of all those 
prescribed 5GPE-SLIT in France was obtained using a 
health insurance database, the Echantillon Généraliste de 
Bénéficiaires (EGB), which represents a permanent sam-
ple of individuals selected at random from 1/97th of the 
nationwide French claims database, consisting of around 
700,000 individuals representative of the French popula-
tion. The EGB database contains information on all eli-
gible medical expenditure reimbursed for each insurance 
beneficiary, including all medication prescribed and the 
date of prescription. All patients in the EGB database 
prescribed 5GPE-SLIT for the first time during the study 
period (December 2014 to February 2015) were identified 
and information extracted on their demographic charac-
teristics and on all prescription of allergy medications.
Study procedures and data collection and outcome 
variables
Since this was an observational study, there were no pro-
tocol-specified study procedures. Data was collected at 
the inclusion visit and at the end of the study (end of the 
pollen season). For patients who did not return for a fol-
low-up consultation at the end of the pollen season, they 
were contacted by telephone by the study coordinating 
centre whenever possible.
Data was collected on paper questionnaires by the 
physician and by the patient. The physician completed 
a medical questionnaire at the inclusion visit and at the 
end of study visit. The patient completed an auto-ques-
tionnaire at the inclusion visit and another at the end of 
study visit.
Variables collected on the physician medical ques-
tionnaire included sociodemographic data on the 
patient, allergy history, comorbidities, previous allergy 
treatments, date of initiation of 5GPE-SLIT and dose, 
concomitant medications and, for the end-of-study 
questionnaire, any modifications to treatment or 
adverse events reported during the pollen season. 
Whether a diagnostic test had been performed was 
documented together with the class of test used (skin 
prick test, specific IgE assay, nasal irritation test) and 
whether the test was positive or not. Participating phy-
sicians followed their routine practice with respect to 
the exact nature of the test (e.g. type of pollen used) 
and the criterion for positivity (e.g. weal size). The 
physician also provided details of their own allergol-
ogy qualifications, where they practiced and their age 
and gender. At inclusion, the patient rated the personal 
importance of 25 treatment needs on a five-point Lik-
ert scale (Patient Needs Questionnaire; PNQ) and then, 
at the end of the study, rated the extent to which these 
same needs were met by treatment (Patient Benefit 
Questionnaire; PBQ). The PNQ-PBQ has previously 
been validated in patients with allergic rhinitis [17] 
and was used here in a validated French translation. A 
treatment impact score, which could range from 0 (no 
impact) to 4 (major benefit), was generated for each 
patient using the data from the PNQ-PBQ [17, 18].
Outcome variables
The primary outcome variable was the compatibility 
of prescription with the recommendations in the pre-
scribing information. These recommendations specify 
the indication for 5GPE-SLIT as “Treatment of grass 
pollen allergic rhinitis with or without conjunctivitis 
in adults, adolescents and children (above the age of 5) 
with clinically relevant symptoms, confirmed by a posi-
tive cutaneous test and/or a positive titre of the specific 
IgE to the grass pollen.” Compatibility was determined 
on the basis of four criteria, namely (1) an interval 
between 5GPE-SLIT initiation and the onset of the pol-
len season ≥ 3  months, (2) age of patient ≥ 5  years, (3) 
symptom frequency rated as intermittent or symptom 
severity rated as mild (4) diagnosis confirmed by a posi-
tive skin-prick test and/or a positive specific IgE assay. 
The time of initiation of 5GPE-SLIT with respect to the 
onset of the pollen season was calculated by compar-
ing the date of the inclusion visit at which 5GPE-SLIT 
was prescribed and the beginning of the pollen season 
as declared by the French aerobiology surveillance net-
work (Réseau National de Surveillance Aérobiologique; 
RNSA). Allergic rhinitis symptoms were categorised as 
intermittent or persistent and mild or moderate-severe 
based on the 2001 ARIA classification [19]. Medica-
tions used were classified according to the ATC system 
[20] and divided into maintenance treatments, taken 
every day to prevent occurrence of allergic symptoms 
and acute treatments taken as needed to control allergy 
symptoms. Adverse events occurring during the 2015 
pollen season were documented at the final study visit 
(or at any unprogrammed intermediate visit) and were 
classified according to the terminology of the Medi-
cal Dictionary for Regulatory Activities (MedRA; 2016 
version).
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Statistics
The target population was established at 450 patients 
(300 adults and 150 children) in order to determine the 
principal study variables with a precision of 2.5–5.7% for 
observed frequencies of 5–50%. In order to achieve this 
target, it was anticipated that ninety participating phy-
sicians would need to recruit an average of five patients 
each. Assuming that certain physicians who accepted to 
participate would not in fact recruit any patients, the tar-
get number of participating physicians was 120 (75% of 
active participants). The analysis was performed on the 
analysable population, defined as all patients fulfilling the 
eligibility criteria, for whom data were available at the 
inclusion visit and at the end of study visit. Separate anal-
yses were performed for adults aged ≥ 18 years and chil-
dren. A comparison between the analysable patient set 
and all patients prescribed 5GPE-SLIT in the EGB data-
base was performed. The analysis was purely descriptive. 
Continuous variables are described as mean values with 
standard deviation (SD), median and range. Categorical 
and ordinal variables are presented as frequency counts 
and percentages. 95% confidence intervals (95% CI) were 
calculated for the principal variables of interest. Miss-
ing data were not imputed. All analyses were performed 
using  SAS® software version 9.3.
Ethical considerations
The study protocol received all legal authorisations from 
the National Medical Council (CNOM), the National 
Advisory Committee on Medical Research Informa-
tion (CCTIRS) and the French national data protec-
tion agency (CNIL). Since the conduct of the study had 
no influence on patient care and there were no specific 
study interventions, ethical committee clearance was 
not required. All patients provided written informed 
consent to be contacted by the study coordinating cen-
tre if necessary, and all nominative data collected in the 
study questionnaires was rendered anonymous before 
entry into the study database. The study was registered 
with the EUPAS registry as 9358 and conducted accord-




Of 1731 allergists contacted, 294 (17.0%) replied to the 
invitation and 193 of these (11.1% of those contacted) 
agreed to participate in the study. Ninety of these physi-
cians enrolled at least one patient. All but four physicians 
considered themselves to have expertise in allergology.
A total of 524 patients were enrolled into the study, of 
whom 483 (280 adults and 203 children) were analysable. 
An end-of-study physician questionnaire was unavailable 
for the remaining 41 patients (reasons unknown), who 
did not return for a follow-up consultation and could not 
be contacted by telephone. These patients thus could not 
be evaluated and were excluded from the analysis popu-
lation (Fig.  1). The sociodemographic and clinical char-
acteristics of the analysable population are presented in 
Table 1. The children were principally boys whilst adults 
were equally divided between men and women. Aller-
gic rhinitis was associated with conjunctivitis in the 
majority of cases. Around half of the patients presented 
other allergic conditions, mostly asthma. During aller-
gic episodes in the previous pollen season, the majority 
of patients presented persistent symptoms which were 
moderate to severe according to the ARIA classification 
[19]. At least one specific grass pollen allergy test had 
been performed in all patients, a skin prick test in all but 
four patients and a specific IgE assay in around half. Dur-
ing the previous pollen season, maintenance treatments 
had been prescribed to three-quarters of the patients 
and acute treatments to a little under half. In both cases, 
systemic antihistamines were the most frequently pre-
scribed medication.
In the reference sample taken from the EGB database, 
seventy health insurance beneficiaries were identified 
who had received a first prescription of 5GPE-SLIT 
during the study period. Overall, the characteristics of 
the analysable patients were comparable to those in the 
EGB sample (Additional file 1: Table S1).
Treatment by 5GPE‑SLIT
Treatment by 5GPE-SLIT was initiated at least 
3  months before the onset of the pollen season, as 
specified in the prescribing information, in 412 patients 
(85.3%), principally during the third month (Fig. 2). The 
mean interval between initiation of 5GPE-SLIT and the 
onset of the pollen season was 109 ± 16 days.
Enrolled paents
N =  524
Analysable populaon






N =  280
Chilldren
N =  203
Fig. 1 Patient disposition
Page 5 of 11Blin et al. Allergy Asthma Clin Immunol  (2018) 14:38 
At least one inconsistency with the recommended pre-
scribing information was found for 13.3% of children 
and 17.5% of adults, mainly with respect to initiation of 
5GPE-SLIT less than 3 months before the start of the pol-
len season (Table 2).
The mean duration of treatment by 5GPE-SLIT was 
5.6 ± 1.9  months in children and 5.2 ± 2.0  months in 
adults. Fifty-three patients (11.0%; 18 children and 
35 adults) had discontinued 5GPE-SLIT before the 
beginning of the pollen season, principally within the 
first 2 months. The principal reason for stopping treat-
ment before the pollen season was the occurrence of 
an adverse event (Table  3). For the remaining patients 
continuing treatment, the mean duration of treatment 
after the onset of the pollen season was 72.9 ± 23.8 days 
in children and 72.7 ± 24.9  days in adults. At the last 
follow-up visit, the majority of patients had discontin-
ued 5GPE-SLIT, usually due to the end of the planned 
Table 1 Demographic and clinical characteristics of the analysable population
ARIA allergic rhinitis and its impact on asthma, SD standard deviation







Gender (n,%; male) 129 (63.5%) 139 (49.6%) 268 (55.5%)
Age (mean ± SD; years) 11.8 (3.4) 33.8 (10.9) 24.5 (13.9)
Smoker or ex‑smoker (n, %) 3 (1.5%) 74 (26.4%) 77 (15.9%)
Living in an urban environment (n, %) 88 (43.3%) 167 (59.6%) 255 (52.8%)
Age at onset of allergic rhinitis (mean ± SD; years) 7.8 (3.3) 18.6 (9.9) 14.1 (9.5)
Allergic rhinitis with conjunctivitis (n, %) 170 (83.7%) 244 (87.1%) 414 (85.7%)
Other allergic conditions (n, %)
 None 90 (44.3%) 143 (51.1%) 233 (48.2%)
 Asthma 84 (41.4%) 96 (34.3%) 180 (37.3%)
 Eczema 32 (15.8%) 30 (10.7%) 62 (12.8%)
 Food allergy 14 (6.9%) 16 (5.7%) 30 (6.2%)
 Urticaria 6 (3.0%) 12 (4.3%) 18 (3.7%)
Other associated chronic disease 9 (4.4%) 20 (7.1%) 29 (6.0%)
Symptom  frequencya (ARIA classification) (n, %)
 Intermittent 30 (14.8%) 34 (12.1%) 64 (13.3%)
 Persistent 173 (85.2%) 246 (87.9%) 419 (86.7%)
Allergy  severitya (ARIA classification) (n, %)
 Mild 15 (7.4%) 4 (1.4%) 19 (3.9%)
 Moderate or severe 188 (92.6%) 276 (98.6%) 464 (96.1%)
Specific grass pollen allergy test performed (n, %) 203 (100.0%) 280 (100.0%) 483 (100.0%)
 Skin prick test 200 (98.5%) 279 (99.6%) 479 (99.2%)
 Anti‑grass pollen IgE assay 113 (55.7%) 143 (51.1%) 256 (53.0%)
 Nasal irritation test None None None
Maintenance treatment previously  prescribeda (n, %) 156 (76.8) 209 (74.6%) 365 (75.6%)
 Systemic antihistamines 142 (70.0%) 195 (69.6%) 337 (69.8%)
 Topical decongestants and other preparations 62 (30.5%) 85 (30.4%) 147 (30.4%)
 Topical corticosteroids 62 (30.5%) 79 (28.2%) 141 (29.2%)
 Systemic decongestants and anti‑allergic drugs 34 (16.7%) 41 (14.6%) 75 (15.5%)
 Inhaled sympathomimetic drugs 21 (10.3%) 12 (4.3%) 33 (6.8%)
 Other 13 (6.4%) 14 (5.0%) 27 (5.6%)
Acute treatment previously  prescribeda (n, %) 101 (49.8%) 119 (42.5%) 220 (45.5%)
 Systemic antihistamines 41 (20.2%) 56 (20.0%) 97 (20.1%)
 Topical decongestants and other preparations 39 (19.2%) 37 (13.2%) 76 (15.7%)
 Topical corticosteroids 38 (18.7%) 27 (9.6%) 65 (13.5%)
 Systemic decongestants and anti‑allergic drugs 42 (20.7%) 45 (16.1%) 87 (18.0%)
 Inhaled sympathomimetic drugs 26 (12.8%) 21 (7.5% %) 47 (9.7%)
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treatment course (Table 3). Only two adult patients dis-
continued treatment during the pollen season due to 
the occurrence of an adverse event. The proportion of 
patients still taking 5GPE-SLIT was 64.7% 60 days into 
the pollen season, 42.5% after 75 days and 19.1% after 
90 days.
Allergy symptoms during 5GPS‑SLIT and comedication
During the 2015 pollen season, 27 children (13.3%) and 
64 adults (22.9%) presented persistent allergy symp-
toms. Allergy severity was rated as moderate-severe for 
69 children (34.0%) and 107 adults (38.2%). Around two-
thirds of all patients evolved from persistent symptoms 
or moderate-severe rhinitis in 2014 to intermittent symp-
toms and mild rhinitis in 2015 whilst taking 5GPE-SLIT 
(Table 4).
For the most frequent symptoms of rhinitis, around 
half the patients who had reported individual symptoms 
during the previous (2014) pollen season, reported that 
these symptoms were absent during the 2015 pollen sea-
son whilst receiving 5GPE-SLIT (Table 5).
During the 2015 pollen season, 141 patients (29.2%; 
53 children and 88 adults) received a maintenance treat-
ment in addition to 5GPE-SLIT. This represents a reduc-
tion of 61.4%, in the proportion of patients prescribed 
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Fig. 2 Time between treatment initiation and onset of pollen season
Table 2 Inconsistency of prescription with the prescribing information
NA not applicable







At least one inconsistency 27 (13.3%) 49 (17.5%) 76 (15.7%)
Children aged < 5 years None NA None
5GPE‑SLIT started < 3 mo before pollen season 23 (11.3%) 48 (17.1%) 71 (14.7%)
Symptoms not clinically  relevanta 4 (14.8%) 1 (2.0%) 5 (6.6%)
No confirmatory diagnostic test of pollen allergy None None None
Table 3 Reasons for discontinuation of 5GPE-SLIT before the end-of-study follow-up visit







Discontinuation before the start of the pollen season N = 18 N = 34 N = 52
 Planned end of treatment course 1 (5.6%) 2 (5.9%) 3 (5.8%)
 Patient decision 2 (11.1%) 3 (8.8%) 5 (9.6%)
 Occurrence of an adverse event 14 (77.8%) 27 (79.4%) 41 (78.8%)
 Other 1 (5.6%) 2 (5.9%) 3 (5.8%)
Discontinuation after the start of the pollen season N = 150 N = 191 N = 341
 Planned end of treatment course 136 (90.7%) 172 (90.1%) 308 (90.3%)
 Patient decision 5 (3.3%) 8 (4.2%) 13 (3.8%)
 Lack of efficacy 1 (0.7%) 1 (0.5%) 2 (0.6%)
 Occurrence of an adverse event None 2 (1.0%) 2 (0.6%)
 Other 3 (2.0%) 1 (0.5%) 4 (1.2%)
 Not documented 5 (3.3%) 7 (3.7%) 12 (3.5%)
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This reduction was observed for all classes of medication 
(Fig.  3). This reduction in prescription of maintenance 
treatments is accompanied by an increase in prescription 
of acute treatments: 297 patients (61.5%; 126 children 
and 171 adults) received at least one prescription dur-
ing 2015, representing an increase of 35.0% compared to 
2014. This increase was particularly noticeable for pre-
scription of systemic antihistamines.
The mean treatment impact score was 2.2 ± 1.0 
(median 2.3) in children and 2.3 ± 0.9 (median 2.4) in 
adults. The treatment impact score was ≥ 1, indicating 
at least some benefits, in 168 children (87.0%) and in 238 
adults (90.5%). The individual items of the patient impact 
score with the largest differences in rating between the 
inclusion and end-of-study visit were itching in the nose, 
eyes or palate, relief of runny or stuffed-up nose and relief 
of all symptoms (Additional file 1: Table S2).
Tolerability
A total of 255 adverse events were reported by 122 
patients during the course of the study. The proportion 
of patients reporting adverse events was similar in chil-
dren (23.2%) and adults (26.8%) (Table  6). The majority 
of these adverse events were considered to be related to 
5GPE-SLIT. The most frequent of these related adverse 
events were throat irritation in 27 patients, oral pruri-
tus in 19 patients and mouth oedema in 12 patients. No 
other related adverse event was reported in more than 
ten patients. Eleven events in four patients were classi-
fied as serious (two cases of dyspnoea, and one case each 
of abdominal pain, throat tightness, lip oedema, gingival 
oedema, swollen tongue, cough, dyspnoea, chest discom-
fort and oropharyngeal discomfort) and nine events in 
eight patients were unexpected (not listed in the sum-
mary of product characteristics), including two cases of 
aphthous ulcers and one case each of mouth mucosal 
rash, gum oedema, papular rash, sensation of suffocat-
ing, sensation of foreign bodies in the eye and nasal ulcer. 
One adverse event (the case of gum oedema) was both 
serious and unexpected.
Discussion
The primary objective of this study was to evaluate the 
coherence of real-world prescription of 5GPE-SLIT with 
the prescribing recommendations. We found that this 
coherence was high, with all conditions of the indication 
being respected for over eight out of ten patients. There 
were no breaches of the prescribing information with 
regard to the lower age limit for prescription to children, 
nor for the requirement for a positive pollen allergy test. 
The principal inconsistency with the prescribing infor-
mation (71 out of 76 cases) related to the initiation of 
treatment less than 3 months before the onset of the pol-
len season. However, it should be noted that it is not pos-
sible to predict exactly when the pollen season will begin, 
and this date may vary considerably from year to year 
depending on meteorological conditions. Prescription of 
5GPE-SLIT is restricted in France to physicians trained 
and experienced in the treatment of allergic disorders. In 
our sample of 90 physicians, 86 considered themselves to 
have expertise in allergology.
In terms of effectiveness, we observed that around two-
thirds of patients improved from persistent to intermit-
tent symptoms and from moderate-severe to mild disease 
compared to the previous pollen season. Around half 
the patients reported the absence of the most frequent 
symptoms of rhinitis during 5GPE-SLIT treatment. In 
terms of numbers needed to treat, this would represent 
a respectable benefit of 5GPE-SLIT. The data are difficult 
to compare with those obtained from interventional clin-
ical trials, due to the use of different measures of efficacy/
effectiveness and much stricter eligibility criteria [21]. 
However, data from the RNSA pollen surveillance net-
work (http://www.polle ns.fr/accue il.php) suggest that the 
2015 pollen season lasted somewhat longer than the 2014 
season and that similar mean maximum pollen counts 







Change in symptom frequency between 2014 and 2015
 Not determined in 2015 2 (1.0%) 6 (2.1%) 8 (1.7%)
 Improved (persistent in 2014/intermittent in 2015) 146 (71.9%) 181 (64.6%) 327 (67.7%)
 Worsened (intermittent in 2014/persistent in 2015) 2 (1.0%) 5 (1.8%) 7 (1.4%)
 Unchanged between 2014 and 2015 53 (26.1%) 88 (31.4%) 141 (29.2%)
Change in allergy severity between 2014 and 2015
 Improved (moderate‑severe in 2014/mild in 2015) 122 (60.1%) 169 (60.4%) 291 (60.2%)
 Worsened (mild in 2014/moderate‑severe in 2015) 3 (1.5%) None 3 (0.6%)
 Unchanged between 2014 and 2015 78 (38.4%) 111 (39.6%) 189 (39.1%)
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were reached in both years. For this reason, it is unlikely 
that the difference in symptom presentation between the 
2 years can be explained by a less intense pollen season 
in 2015.
Compared to the previous pollen season, the use of 
other maintenance treatments was reduced by two-
thirds. This would be expected since 5GPE-SLIT is 
prescribed instead of these medications in order to 
prevent allergic rhinitis symptoms. This reduction is 
compensated by an increase of prescription of the same 
medication for acute use on an as-needed basis, notably 
of systemic antihistamines. This may be a way to ensure 
that patients have a stock of medication available and 
ready to use in case of symptom occurrence. In terms of 
cost-saving, this might be a drawback.
The tolerability of 5GPE-SLIT in this study was accept-
able and consistent with what is known of the safety pro-
file of the medication [22]. The most frequent adverse 
Table 5 Evolution of symptoms between the previous (2014) and current (2015) pollen seasons
Children (N = 203) Adults (N = 283)
2014 pollen season 2015 pollen season 2014 pollen season 2015 pollen season
Reported symptoms, n (%)
 Unilateral nose symptoms 27 (13.3%) 23 (11.3%) 35 (12.5%) 53 (18.9%)
 Viscous purulent rhinorrhoea 12 (5.9%) 1 (0.5%) 7 (2.5%) 13 (4.6%)
 Abundant rhinorrhoea/posterior draining 94 (46.3%) 38 (18.7%) 154 (55.0%) 66 (23.6%)
 Facial pain 15 (7.4%) 5 (2.5%) 51 (18.2%) 18 (6.4%)
 Recurrent nose bleeds 28 (13.8%) 17 (8.4%) 15 (5.4%) 12 (4.3%)
 Hypo‑osmia 57 (28.1%) 18 (8.9%) 94 (33.6%) 44 (15.7%)
Reported symptoms most days, n (%)
 Watery rhinorrhoea 191 (94.1%) 102 (50.2%) 276 (98.6%) 130 (46.4%)
 Repetitive sneezing 192 (94.6%) 91 (44.8%) 275 (98.2%) 145 (51.8%)
 Blocked nose 171 (84.2%) 84 (41.4%) 243 (86.8%) 93 (33.2%)
 Nasal pruritus 154 (75.9%) 76 (37.4%) 243 (86.8%) 115 (41.1%)
 Signs of conjunctivitis 171 (84.2%) 86 (42.4%) 252 (90.0%) 118 (42.1%)
Symptom frequency, n (%)
 Less than 4 days per week 19 (9.4%) 151 (74.4%) 23 (8.2%) 183 (65.4%)
 More than 4 days per week 184 (90.6%) 50 (24.6%) 257 (91.8%) 90 (32.1%)
Symptom duration, n (%)
 Less than 4 weeks 17 (8.4%) 156 (76.8%) 16 (5.7%) 175 (62.5%)
 More than 4 weeks 186 (91.6%) 46 (22.7%) 264 (94.3%) 100 (35.7%)
Symptom impact: sleep, n (%)
 Normal 104 (51.2%) 174 (85.7%) 120 (42.9%) 227 (81.1%)
 Disturbed 99 (48.8%) 29 (14.3%) 160 (57.1%) 53 (18.9%)
Symptom impact: social and recreational activities, n (%)
 Normal 83 (40.9%) 174 (85.7%) 95 (33.9%) 234 (83.6%)
 Disturbed 120 (59.1%) 27 (13.3%) 185 (66.1%) 46 (16.4%)
Symptom impact: professional and/or school activities, n (%)
 Normal 95 (46.8%) 29 (14.3%) 116 (41.4%) 232 (82.9%)
 Disturbed 108 (53.2%) 172 (84.7%) 163 (58.2%) 47 (16.8%)
Symptom impact: uncomfortable symptoms, n (%)
 Not particularly uncomfortable 20 (9.9%) 155 (76.4%) 11 (3.9%) 199 (71.1%)
 Uncomfortable 183 (90.1%) 48 (23.6%) 269 (96.1%) 81 (28.9%)
Symptom frequency, n (%)
 Intermittent 30 (14.8%) 174 (85.7%) 34 (12.1%) 210 (75.0%)
 Persistent 173 (85.2%) 27 (13.3%) 246 (87.9%) 64 (22.9%)
Allergy severity, n (%)
 Mild 15 (7.4%) 134 (66.0%) 4 (1.4%) 173 (61.8%)
 Moderate or severe 188 (92.6%) 69 (34.0%) 276 (98.6%) 107 (38.2%)
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events reported were local oropharyngeal reactions such 
as throat irritation, oral pruritus and mouth oedema. As 
expected for an observational study, the rate of adverse 
event reporting was lower than that reported in inter-
ventional clinical trials [22]. Forty-three patients discon-
tinued 5GPE-SLIT due to the occurrence of an adverse 
event, but this happened before the start of the pollen 
season for all but two patients. Discontinuation before 
the start of the pollen season does not deprive the patient 
of a potentially successful therapy, since an alternative 
prophylactic treatment can be introduced.
Little published information is available on real-world 
use of 5GPE-SLIT. In a large multicentre observational 
study involving over 1400 patients with clinically relevant 
allergic symptoms caused by grass pollen performed in 
Germany [23], a fifty percent reduction in a combined 
rhinoconjunctivitis score compared to the previous pol-
len season was observed, associated with an improve-
ment in overall health perceptions and a low occurrence 
of adverse drug reactions. Similarly, in the SMILE study 
in Spain [24], conducted in 226 patients with allergic rhi-
noconjunctivitis, a reduction of fifty percent in the pro-
portion of patients with persistent moderate or severe 
AR was reported following initiation of 5GPE-SLIT, with 
concomitant improvements in symptoms and quality of 
life and a reduction in the use of concomitant anti-aller-
gic medications. Our findings are essentially consistent 
with those of these previous observational studies.













Proporon of paents (%)
2015 pollen season
2014 pollen season
Fig. 3 Comparison of prescription rates for acute and maintenance treatments for allergic rhinitis between the 2014 (grey square) and 2015 (black 
square) pollen seasons
Table 6 Adverse events reported during the study
Italic represents the number of adverse events (one patient could have several dares event, and could be removed for the 3 last items (unexpected adverse events, 
serious adverse events, unexpected and serious adverse events)














Adverse events related to 5GPE‑SLIT







Unexpected adverse events related to 5GPE‑SLIT
Number of adverse events
3 (1.5%) 5 (1.8%) 8 (1.7%)
Serious adverse events related to 5GPE‑SLIT
Number of adverse events
2 (1.0%) 2 (0.7%) 4 (0.8%)
11
Serious and unexpected adverse events related to 5GPE‑SLIT
Number of adverse events
None 1 (0.4%) 1 (0.2%)
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This study has a number of strengths and limitations. 
The strengths include the relatively large number of 
patients enrolled, corresponding to around 6% of all 
patients prescribed 5GPE-SLIT in France during the 
2015 pollen season, and the low proportion of patients 
lost to follow-up (< 10%). In addition, a broad range of 
clinical variables, and their evolution over the course 
of the 2015 pollen season, were documented. The 
principal limitations are those inherent to all observa-
tional studies. Given that patients were recruited by a 
small number of voluntary participating physicians, an 
inclusion bias cannot be excluded. In this context, it is 
noteworthy that 68% of patients in the EGB reference 
sample were prescribed 5GPE-SLIT by their general 
practitioner, compared to only 24% in our study. The 
practice of participating physicians may thus not be 
representative of physicians prescribing 5GPE-SLIT in 
France. Nonetheless, the characteristics of the patients 
in our study are similar to those of the patients in the 
EGB reference sample. A second limitation is that there 
is no way of ascertaining whether the patients took 
their 5GPE-SLIT as prescribed, or that other prescrip-
tion medication evaluated (maintenance and acute 
treatments) were actually used.
In conclusion, this observational study has shown 
that, in real-world clinical practice, 5GPE-SLIT is pre-
scribed consistently with the prescribing information 
and presents a benefit-risk profile to that anticipated 
from the clinical trial programme.
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